Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry

American Journal of Clinical Pathology

Volumn 119, Issue 5, 2003, Pages 643-655

  Chang, Anthony ^b   Benda, Peter M ^b   Wood, Brent L ^b   Kussick, Steven J ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

CD56; CD90; CD99; Cytokeratin; EpCAM; Epithelial glycoprotein 2; Flow cytometry; Myogenin; Nonhematopoietic neoplasm

Indexed keywords

CD99 ANTIGEN; CELL PROTEIN; CHROMOGRANIN; CYTOKERATIN; CYTOKERATIN 7; DESMIN; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL GLYCOPROTEIN 2; FLUORESCEIN ISOTHIOCYANATE; MEMBRANE ANTIGEN; MYOGENIN; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN; THY 1 ANTIGEN; UNCLASSIFIED DRUG; CD45 ANTIGEN; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; KERATIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CARCINOID; CARCINOMA; CELL LINEAGE; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; EWING SARCOMA; FEMALE; FLOW CYTOMETRY; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MELANOMA; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SEMINOMA; SMALL CELL CARCINOMA; THYROID MEDULLARY CARCINOMA; FEASIBILITY STUDY; IMMUNOPHENOTYPING; NEOPLASM; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, NEOPLASM; ANTIGENS, THY-1; CARCINOMA; CELL ADHESION MOLECULES; CELL LINEAGE; FEASIBILITY STUDIES; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KERATINS; MYOGENIN; NEOPLASMS; RHABDOMYOSARCOMA;

EID: 85047688608     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FU3FDKYN8AU0891N     Document Type: Article

References (33)

1. Komada Y, Zhang XL, Zhou YW, et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer. 1998;82:591-599.
2. Kussick SJ, Wood BW, Li Y. Using antibodies to CD56 and CD45 to identify nonhematopoietic small blue round cell tumors by flow cytometry [abstract]. Am J Clin Pathol. 2001;116:279.
3. Sanchez-Carbayo M, Ciudad J, Urrutia M, et al. Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma. Cancer. 2001;92:2811-2819.
4. Davidson B, Dong HP, Berner A, et al. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping. Am J Clin Pathol. 2002;118:85-92.
5. Bryson GJ, Lear D, Williamson R, et al. Detection of the CD56+/CD45-immunophenotype by flow cytometry in neuroendocrine malignancies. J Clin Pathol. 2002;55:535-537.
6. De Leij L, Helrich W, Stein R, et al. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl. 1994;8:60-63.
7. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77:699-712.
8. Soosay GN, Griffiths M, Papadaki L, et al. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Pathol. 1991;163:299-305.
9. Robinson RJ, Royston D. Comparison of monoclonal antibodies AUA1 and BER EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathology. 1993;4:267-271.
10. Kocjan G, Sweeney E, Miller KD, et al. AUA1: new immunocytochemical marker for detecting epithelial cells in body cavity fluids. J Clin Pathol. 1992;45:358-359.
11. Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol. 2000;13:988-993.
12. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? a study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol. 2001;25:1150-1157.
13. Devoe K, Weidner N. Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol. 2000;17:216-224.
14. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28:1373-1378.
15. Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol. 2000;17:194-203.
16. Dunphy CH. Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma? Cytometry. 2000;42:296-306.
17. Gardner LJ, Polski JM, Fallon R, et al. Identification of CD56 and CD57 by flow cytometry in Ewing's sarcoma or primitive neuroectodermal tumor. Virchows Arch. 1998;433:35-40.
18. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol. 2000;22:20-26.
19. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993;259:1450-1453.
20. Ladanyi M, Lewis R, Jhanwar SC, et al. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol. 1995;175:211-217.
21. Yamamoto K, Hamaguchi H, Nagata K, et al. Establishment of a novel human acute myeloblastic leukemia cell line (YNH-1) with t(16;21), t(1;16) and 12q13 translocations. Leukemia. 1997;11:599-608.
22. Brox AG, Lavallee MC, Arseneau J, et al. Expression of common acute lymphoblastic leukemia-associated antigen on germ cell tumor. Am J Med. 1986;80:1249-1252.
23. Smithey BE, Pappo AS, Hill DA. c-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol. 2002;26:486-492.
24. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188-193.
25. Ricotti E, Fagioli F, Garelli E, et al. c-kit is expressed in soft tissue sarcoma of neuroectodermal origin and its ligand prevents apoptosis of neoplastic cells. Blood. 1998;91:2397-2405.
26. Landuzzi L, De Giovanni C, Nicoletti G, et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol. 2000;157:2123-2131.
27. Li G, Passebosc-Faure K, Lambert C, et al. Flow cytometric analysis of antigen expression in malignant and normal renal cells. Anticancer Res. 2000;20:2773-2778.
28. Moreno JG, O'Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58:386-392.
29. Leers MPG, Schoffelen RHMG, Hoop JGM, et al. Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol. 2002;55:359-366.
30. Sumikuma T, Shimazaki C, Inaba T, et al. CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol. 2002;117:238-244.
31. Romero-Ramos M, Vourc'h P, Young HE, et al. Neuronal differentiation of stem cells isolated from adult muscle. J Neurosci Res. 2002;69:894-907.
32. Young HE, Steele TA, Bray RA, et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec. 2001;264:51-62.
33. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104-3112.